AKÖZ Mehmet, Burhan APİLİOĞULLARI, Murat ÖNCEL, Aysel KIYICI, Müfide ÖNCEL

MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels in epidermoid lung cancer

To investigate serum levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 complex in epidermoid lung cancer and determine whether one of these markers or any combination of them can be used as a prognostic factor and in the management of this disease. Materials and methods: Twenty-eight patients with non-small cell lung cancer and 21 healthy, age-matched individuals participated in this study. MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were measured in the sera of the patients and controls with the ELISA technique. Results: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were significantly elevated in patients with non-small cell lung cancer compared to the controls (P = 0.018, 0.041, and 0.034, respectively). Conclusion: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels increased not only in lung tissues, but in the sera of the patients with non-small cell lung cancer. However, further studies are needed to fully evaluate the expression rates and diagnostic efficiency of these parameters in different histopathological subtypes of this cancer and in prospective research with a large number of participants.

Anahtar Kelimeler:

Key words: Epidermoid lung cancer, MMP-2, TIMP-2, MMP-2/TIMP-2 complex

MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels in epidermoid lung cancer

Keywords:

Key words: Epidermoid lung cancer, MMP-2, TIMP-2, MMP-2/TIMP-2 complex,

PDF

___

Kırgıl G, Deveci F, Turgut T, Muz HM, Kaçar C. Akciğer kanserinin epidemiyolojik özelliklerinin retrospektif olarak karşılaştırmalı değerlendirilmesi. F.Ü. Sağlık Bilimleri Dergisi 2005; 19: 165–9.
Shih JY, Tsai MF, Chang TH, Chang YL, Yuan A, Yu CJ et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 2005; 11: 8070–8078.
Apakkan AS, Bayındır O, Özmen D. Metalloproteinazlar, inhibitörleri ve ilişkili fizyolojik ve patolojik durumlar. Turk Klin Tıp Bilim 2001; 21: 332–42.
Hewitt R, Dan K. Stromal cell expression of components of matrix degrading protease systems in human cancer. Enzyme Protein 1996; 49: 163–73.
Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121–5.
Sethi CS, Bailey TA, Luthert PJ, Chong NHV. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 2000; 84: 654–64.
Oğuz SH, Çamlıca H, Duranyılmaz D, Kaytan Sağlam E, Taş F, Yasasever V et al. Matriks metalloproteinazlar ve akciğer kanseri. Turk Onkol Der 2006; 21: 53–6.
Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G et al. Pretreatment serum levels of matrix metalloproteinase–9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 2002; 13: 1550–7.
Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase–9 in non-small cell lung cancer patients. Clin Chim Acta 2005; 354: 91–9.
Güllü IH, Kurdoğlu M, Akalin I. The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. British Journal of Cancer 2000; 82: 246–249.
Akalin İ, Güllü İH, Kurdoğlu M, Marangoz S. Why hepatocellular carcinoma cells are unlikely to metastasize: is there a role for tissue inhibitor of metalloproteinase-1? Med Hypotheses 2001; 57: 221–3.
Kurdoğlu M, Güllü İH, Akalin İ. Is there a relationship between tissue inhibitor of metalloproteinase-1 and transforming growth factor-beta 1 with respect to malignant melanoma progression? Med Hypotheses 2001; 57: 238–40.
Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–4.
Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187–98.
Chia MM, Gazdar AF, Carbone DP, Minna JD. Neoplasms of the lungs. In: Murray JF, Nadel JA, editors. Textbook of Respiratory Medicine 2nd ed. W.B. Saunders Company, Philadelphia; 1994. p. 1485–1503.
Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002; 29: 78–86.
Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6: 3944–8.
Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 2002; 35: 249–55.
Cox G, Jones JL, Andi A, Waller DA, O’Byrne KJ. A biological staging model for operable non-small cell lung cancer. Thorax 2001; 56: 565–6.
Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F et al. Differential expression of E-caherin and type IV collagenase genes predicts outcome in patient with stage I non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 790–7.
Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001; 95: 1–4.
Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T et al. Elevated levels of circulating plasma metalloproteinase 9 in non-small cell lung cancer patient. Clin Cancer Res 1999; 5: 49–53.
Yurdakul A, Akyürek N, Karakaya J, Memiş L, Öztürk C. Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turk J Med Sci 2012; 42: 281–288.
Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y et al. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 2000; 27: 19–26.
Eren B, Sar M, Oz B, Dincbas F. MMP-2, TIMP-2 and CD44v6 in non-small cell lung carcinomas. Ann Acad Med Singapore 2008; 37: 32–9.
Iniesta P, Morán A, De Juan C, Gómez A, Hernando F, García- Aranda C et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 2007; 17: 217–23.
Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T, Maehara Y. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today 2004; 34: 896–901.
Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000; 20: 1311–6.
Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993; 68: 4–17.
Hida Y, Hamada JI. Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers. Anticancer Agents Med Chem 2012 [Epub ahead of print].
Lim BJ, Jung SS, Choi SY, Lee CS. Expression of metastasis- associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Report 2010; 3: 43–9.
Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999; 17: 1802–8.
Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4548–9.
Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B et al. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol 2011; 179: 2589–600.